Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

33.89 +2.77 (+8.90%)

Streaming Delayed Price Updated: 3:50 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

Analyst Expectations for Beam Therapeutics's Future ↗

October 17, 2023

Via Benzinga

2 Cathie Wood Stocks I'm Bullish On ↗

October 05, 2023

These two next-gen biotechs could be outstanding buys for patient investors.

Via The Motley Fool

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? ↗

October 03, 2023

The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.

Via The Motley Fool

Cathie Wood's Ark Invest Sells Nearly $4M Worth Of NVIDIA Shares — Does It Herald Shift To Undervalued AI Gems? ↗

October 02, 2023

On Monday, Cathie Wood-led Ark Invest made a notable move by selling nearly $4 million worth of NVIDIA Corp (NASDAQ:NVDA) shares. This ...

Via Benzinga

Topics Artificial Intelligence

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

September 29, 2023

The iconic money manager has struggled the last two months. Let's see what she's buying to get back on track.

Via The Motley Fool

Cathie Wood's Ark Invest Tweaks Portfolio, Sells $1.8M Worth Of DraftKings Shares ↗

September 28, 2023

Via Benzinga

4 Analysts Have This to Say About Beam Therapeutics ↗

August 29, 2023

Via Benzinga

2 Supercharged Growth Stocks That Could Make You Richer ↗

July 15, 2023

These two companies could disrupt healthcare on a global scale.

Via The Motley Fool

2 Magnificent Growth Stocks to Buy On the Dip ↗

September 27, 2023

It might be time to catch these falling knives.

Via The Motley Fool

3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too ↗

September 22, 2023

Cathie Wood is loading up on these healthcare stocks.

Via The Motley Fool

2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss ↗

September 19, 2023

The gene-editing market is moving fast, and it pays to get to know some of these companies.

Via The Motley Fool

Here's the 1 Cathie Wood Stock Most Likely to Turn $100,000 Into $1 Million Over the Next 20 Years ↗

September 17, 2023

There's no guarantee that any stock will be a millionaire-maker. But the chances for this one look pretty good.

Via The Motley Fool

This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It. ↗

September 08, 2023

The decline of Beam's stock says little about its long-term potential, according to Wood.

Via The Motley Fool

Cathie Wood's Buying These 3 Stocks Hand Over Fist ↗

September 08, 2023

A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team.

Via The Motley Fool

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

September 07, 2023

First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Keeps Shedding Shopify Nvidia Shares, Loads Up On Spotify Stock ↗

September 05, 2023

Via Benzinga

Beam Therapeutics' Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy ↗

September 05, 2023

Beam Therapeutics Inc (NASDAQ: BEAM) announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic

Via Benzinga

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

September 05, 2023

BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in Upcoming September Investor Conferences

August 31, 2023

From Beam Therapeutics

Via GlobeNewswire

Why Is Apellis Pharmaceuticals Stock Trading Lower Today? ↗

August 29, 2023

Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and

Via Benzinga

3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street ↗

August 26, 2023

These cutting-edge biotech stocks could deliver life-changing gains for early shareholders.

Via The Motley Fool

Got $200? 3 Growth Stocks to Buy That Could Double Your Money ↗

August 19, 2023

There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good.

Via The Motley Fool

Cathie Wood's Ark Invest Sells More Tesla Stock — Acquires Shares Of Flying Taxi Company ↗

August 15, 2023

Via Benzinga

Cathie Wood's Ark Invest Sells $2.15M Of Tesla Shares Despite Own Bullish Projections ↗

August 14, 2023

Via Benzinga

Credit Suisse Maintains Neutral Rating for Beam Therapeutics: Here's What You Need To Know ↗

August 09, 2023

Via Benzinga

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

August 08, 2023

From Beam Therapeutics

Via GlobeNewswire

3 Pharma Stocks That AI is Loving in July ↗

July 13, 2023

Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks.

Via InvestorPlace

Verve Therapeutics Gains 20.74% In June as Ark Funds Invest

June 30, 2023

Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June.

Via MarketBeat

Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy ↗

June 18, 2023

Success could be in the DNA of the Ark Invest founder.

Via The Motley Fool

Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? ↗

May 21, 2023

It's facing a few issues that are practically guaranteed to affect shareholder returns.

Via The Motley Fool

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.